Surgical aortic valve replacement is the treatment of choice in patients with severe symptomatic aortic valve
stenosis because it provides excellent early and long-term clinical outcomes in terms of hemodynamics, valve durability,
and freedom from valve-related complications. In recent years, the number of high-risk patients being referred for surgical
aortic valve replacement has increased. A considerable proportion of these patients are deemed operable despite the high
risk. In order to modify the risk predominantly associated with duration of cardiopulmonary bypass and cross clamp time
sutureless aortic valve technology has been developed. Sutureless aortic bioprosthetic valves, introduced in clinical practice
in 2009, contrary to the conventional surgical technique for implantation (interrupted or continuous sutures, after
thorough annular decalcification) are not hand sewn. This technological modification reduces the implantation time with
potential translation into improved outcomes for high-risk patients undergoing surgical aortic valve replacement. Currently,
three sutureless bioprostheses are available and amongst these the largest published experience is available for the
patented and CE marked truly sutureless PERCEVAL S valve (Sorin Group, Saluggia, Italy). This article provides an
overview of the published literature for Perceval S valve with an attempt to better define the role of sutureless aortic valve
replacement in the treatment of critical aortic valve stenosis.
Aortic valve, aortic valve replacement, bioprosthetic valve, sutureless aortic valve, valve replacement.
Department of Cardiac Surgery, Harefield Hospital, London, United Kingdom.